Navigation Links
t2cure First Company to Have Quality of Cellular Therapeutic Certified by EMA
Date:5/25/2010

FRANKFURT, May 25, 2010 /PRNewswire/ -- t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the quality of its lead product t2c001 has been certified by the European Medicines Agency (EMA).

t2c001 is the first product ever to obtain a certificate under the EMA regulations for Advanced Therapy Medicinal Products (ATMPs). It is a somatic cell therapy product derived from autologous bone marrow, that is currently developed for the treatment of cardiovascular diseases. ATMPs are advanced biotechnology products based on cell therapy, gene therapy, or tissue engineering.

"We are absolutely excited that our lead product has been confirmed to meet the rigorous quality requirements set by the EMA, the regulatory body that will decide on a future European market approval for our product", commented Dr Petra Rueck, CEO of t2cure. "Together with upcoming 5-year efficacy and safety data from our Phase II trial, the EMA Certification shows that we are on the right track to bring this groundbreaking therapy closer to the market, and to patients."

Rueck continued: "This achievement also proves that the regulations set out by the EMA for advanced therapy products and the expertise brought together by the EMA's Committee for Advanced Therapies effectively assist small and medium-sized companies in developing advanced therapy products. These products offer novel treatment opportunities for patients who suffer from diseases, including orphan diseases, for which there are limited or no treatment options."

ATMPs and European Regulation on ATMPs

Advanced therapy medicinal products (ATMPs) based on cell therapy, gene therapy, or tissue engineering are at the forefront of biotechnology and medical innovation. Because of their novelty and complexity, evaluating the quality, safety, and efficacy of ATMPs often requires the development of alternative approaches that go beyond what is needed for conventional medicines. For example, testing the stability of a cell therapy product containing living cells derived from the patient's body requires a fundamentally different methodology from testing traditional pharmaceuticals.

In response to these challenges the European Regulation 1394/2007 provided a consolidated framework for this innovative class of products, including a procedure allowing small and medium-sized companies to voluntarily apply for the Certification of the pharmaceutical quality and the pre-clinical data of an advanced therapy product.

While the Certification procedure is independent from a Marketing Authorization Application (MAA), it follows the scientific and technical requirements necessary to facilitate a future MAA. The Certification confirms that the data submitted for an ATMP meet the same scientific and technical standards that apply to current regulation of other pharmaceutical and biotechnology products, including among others requirements regarding GMP, GCP, and stability.

A Certificate issued by the European Medicines Agency (EMA) is based on the evaluation by the members of its Committee for Advanced Therapies (CAT). The CAT is a multidisciplinary committee bringing together several of the best available European experts to assess the quality, safety, and efficacy of advanced therapy products.

For more information on the European ATMP regulation, including on CAT members and on the Certification procedure, see http://www.ema.europa.eu/htms/human/advanced_therapies/intro

About t2cure GmbH

t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops and markets autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular diseases including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease), non-ischemic heart failure and peripheral arterial disease. The most advanced project (t2c001-AMI) has successfully passed Phase II of clinical development and is commercially available to treat patients in Germany.

t2cure is privately financed by Entrepreneurs Fund and Kreditanstalt fuer Wiederaufbau.

    For more information on the Company, visit our website
http://www.t2cure.com

    Company contact:

    Dr. Petra Rueck
    t2cure GmbH
    Bettinastrasse 35-37
    D-60325 Frankfurt am Main
    Tel: +49-69-75-61-46-87-0
    Fax: +49-69-75-61-46-87-9
    Email: info@t2cure.com
    http://www.t2cure.com

    Media contact:

    Frank Butschbacher
    Investor Relations & Communications
    http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net



'/>"/>
SOURCE t2cure GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
2. t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
5. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
6. Genmab Announces 2007 First Half Year Results
7. Pharsight Achieves First License Sale for Public-Source Database
8. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. China Medical Technologies Reports First Quarter Financial Results
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 3, 2016 - And ... and Producers of Those Competitor Biologics  - ... Activities and Prospects ,  Who are the ... And what are their sales potentials? Discover, in our ... results, trends, opportunities and revenue forecasting. ...
(Date:5/2/2016)... 2016 Q BioMed Inc. (QBIO), ... Mannin Research Inc. will be attending the Association for ... from May 1-5, 2016 in Seattle Washington ... its vendors and research partners. The meeting provides organizations ... other collaborative opportunities for the MAN-01 program for treatment ...
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design ... the bioLogic team explored how bacterial properties can be applied to fabric and formed ... bacteria, which move in response to humidity change. The team harvested Natto cells and ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... necessary fundamentals to transform technology into a viable company, CereScan’s CEO, John Kelley, ... Mr. Kelley, a recognized leader and mentor in the Denver area business community, ...
Breaking Biology Technology:
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):